In the Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma with PCV or Temozolomide (NOA-04) and the Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC) trials, patients with MGMT methylation survived approximately three months longer than their peers regardless of treatment modality [2]. The gene discussed is MGMT; the disease is central nervous system cancer.